Insider Transaction Report for Michael Holder

Michael Holder, a director at Cytek Biosciences, Inc. (CTKB), reported a transaction on August 18, 2026. The transaction involved the acquisition of 2,181 shares of Common Stock, acquired at a price of $0.0 per share, resulting in a post-transaction holding of 62,875 shares. Additionally, Holder was granted 2,181 Restricted Stock Units (RSUs), which represent a contingent right to receive one share of common stock each. These RSUs have a post-transaction holding of 7,276 shares and are subject to a vesting schedule over three years, with initial vesting occurring on August 18, 2024, and subsequent vesting dates spread throughout November 2024, March 2025, May 2025, and August 2025.